Zoetis (NYSE: ZTS) reported Q3 EPS of $0.83, $0.06 better than the analyst estimate of $0.77. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.46 billion.

• Reports Revenue of $1.5 Billion, Growing 10%, and Net Income of $347 Million, or $0.71 per Diluted Share, Growing 16%, on a Reported Basis for Third Quarter 2018
• Reports Adjusted Net Income of $403 Million, or Adjusted Diluted EPS of $0.83, for Third Quarter 2018
• Delivers 12% Operational Growth in Revenue and 32% Operational Growth in Adjusted Net Income for Third Quarter 2018
• Updates Full Year 2018 Revenue Guidance to $5.750 - $5.800 Billion and Diluted EPS of $2.81 - $2.90 on a Reported Basis, or $3.08 - $3.13 on an Adjusted Basis

“Zoetis continued delivering strong results in the third quarter, with 12% operational growth in revenue and 32% operational growth in adjusted net income,” said Juan Ramón Alaix, Chief Executive Officer of Zoetis. “Our companion animal products performed well, primarily based on our key dermatology brands, new parasiticides and the addition of the Abaxis diagnostics portfolio. Meanwhile, in livestock products, our swine, poultry and fish portfolios each delivered double-digit growth, with more modest growth in our cattle business. Our diverse portfolio provided us with steady performance across markets, species and therapeutic areas, and we continue to invest internally and externally to support future growth.”

“We are confident in our improved guidance as we complete 2018, and we expect to continue fulfilling our shareholder value proposition – growing revenue in line with or faster than the market, and growing adjusted net income faster than revenue – in the coming years,” said Alaix.

GUIDANCE:

Zoetis sees FY2018 EPS of $3.08-$3.13, versus the consensus of $3.07. Zoetis sees FY2018 revenue of $5.75-5.8 billion, versus the consensus of $5.77 billion.

For earnings history and earnings-related data on Zoetis (ZTS) click here.